Johnson & Johnson (JNJ) Debt to Equity (2009 - 2026)
Johnson & Johnson recorded quarterly Debt to Equity of $0.68 in Q1 2026, up 15.22% quarter-over-quarter from $0.59 in Q4 2025, and up 1.25% year-over-year from $0.67 in Q1 2025.
Johnson & Johnson's Debt to Equity history runs 18 years deep, the most recent figure standing at $0.68 for Q1 2026.
- In Q1 2026, Debt to Equity rose 1.25% year-over-year to $0.68; the TTM figure through Mar 2026 stood at $0.68 (up 1.25% YoY), while the FY2025 annual figure was $0.59, up 14.71% from the prior year.
- Debt to Equity came in at $0.68 for Q1 2026 at Johnson & Johnson, up from $0.59 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.75 in Q2 2023 to a low of $0.42 in Q4 2023.
- A 5-year average of $0.54 and a median of $0.51 in 2024 frame the typical range for Debt to Equity.
- Across the five-year window, Debt to Equity jumped 68.26% in 2023 and sank 35.66% in 2024, its largest moves.
- Johnson & Johnson's Debt to Equity stood at $0.43 in 2022, then slipped by 0.66% to $0.43 in 2023, then increased by 20.15% to $0.51 in 2024, then rose by 14.71% to $0.59 in 2025, then advanced by 15.22% to $0.68 in 2026.
- According to Business Quant data, Debt to Equity over the past three periods registered $0.68, $0.59, and $0.58 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 1.39 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 0.68 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -9.70 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.72 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.22 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 1.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 0.68 |
| Dec 28, 2025 | 0.59 |
| Sep 28, 2025 | 0.58 |
| Jun 29, 2025 | 0.65 |
| Mar 30, 2025 | 0.67 |
| Dec 29, 2024 | 0.51 |
| Sep 29, 2024 | 0.51 |
| Jun 30, 2024 | 0.58 |
| Mar 31, 2024 | 0.48 |
| Dec 31, 2023 | 0.43 |
| Oct 1, 2023 | 0.42 |
| Jul 2, 2023 | 0.60 |
| Apr 2, 2023 | 0.75 |
| Jan 1, 2023 | 0.52 |
| Oct 2, 2022 | 0.43 |
| Jul 3, 2022 | 0.43 |
| Apr 3, 2022 | 0.44 |
| Jan 2, 2022 | 0.46 |
| Oct 3, 2021 | 0.48 |
| Jul 4, 2021 | 0.48 |
| Apr 4, 2021 | 0.51 |
| Jan 3, 2021 | 0.56 |
| Sep 27, 2020 | 0.20 |
| Jun 28, 2020 | 0.48 |
| Mar 29, 2020 | 0.45 |
| Dec 29, 2019 | 0.47 |
| Sep 29, 2019 | 0.50 |
| Jun 30, 2019 | 0.48 |
| Mar 31, 2019 | 0.50 |
| Dec 30, 2018 | 0.51 |
| Sep 30, 2018 | 0.48 |
| Jul 1, 2018 | 0.51 |
| Apr 1, 2018 | 0.51 |
| Dec 31, 2017 | 0.57 |
| Oct 1, 2017 | 0.48 |
| Jul 2, 2017 | 0.48 |
| Apr 2, 2017 | 0.46 |
| Jan 1, 2017 | 0.39 |
| Oct 2, 2016 | 0.37 |
| Jul 3, 2016 | 0.36 |
| Apr 3, 2016 | 0.32 |
| Jan 3, 2016 | 0.28 |
| Sep 27, 2015 | 0.28 |
| Jun 28, 2015 | 0.27 |
| Mar 29, 2015 | 0.28 |
| Dec 28, 2014 | 0.27 |
| Sep 28, 2014 | 0.20 |
| Jun 29, 2014 | 0.22 |
| Mar 30, 2014 | 0.23 |
| Dec 29, 2013 | 0.25 |
| Sep 29, 2013 | 0.22 |
| Jun 30, 2013 | 0.22 |
| Mar 31, 2013 | 0.24 |
| Dec 30, 2012 | 0.25 |
| Sep 30, 2012 | 0.26 |
| Jul 1, 2012 | 0.29 |
| Apr 1, 2012 | 0.32 |
| Jan 1, 2012 | 0.34 |
| Oct 2, 2011 | 0.30 |
| Jul 3, 2011 | 0.30 |
| Apr 3, 2011 | 0.30 |
| Jan 2, 2011 | 0.30 |
| Oct 3, 2010 | 0.21 |
| Jul 4, 2010 | 0.22 |
| Apr 4, 2010 | 0.23 |
| Jan 3, 2010 | 0.29 |
| Sep 27, 2009 | 0.23 |
| Jun 28, 2009 | 0.29 |